PP
GILD icon

PFS Partners’s Gilead Sciences GILD Stock Holding History

PFS Partners’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.1K Hold
95
– – ﹤0.01% 363
2026
Q1 		$13.2K Buy
95
+1
+1% +$140 0.01% 324
2025
Q4 		$11.6K Hold
94
– – 0.01% 340
2025
Q3 		$10.4K Buy
94
+1
+1% +$114 ﹤0.01% 337
2025
Q2 		$10.3K Buy
93
+91
+4,550% +$9.69K 0.01% 310
2025
Q1 		$260 Hold
2
– – ﹤0.01% 428
2024
Q4 		$213 Hold
2
– – ﹤0.01% 436
2024
Q3 		$192 Hold
2
– – ﹤0.01% 438
2024
Q2 		$156 Hold
2
– – ﹤0.01% 430
2024
Q1 		$165 Hold
2
– – ﹤0.01% 450
2023
Q4 		$180 Hold
2
– – ﹤0.01% 451
2023
Q3 		$165 Hold
2
– – ﹤0.01% 454
2023
Q2 		$168 Hold
2
– – ﹤0.01% 473
2023
Q1 		$179 Hold
2
– – ﹤0.01% 381
2022
Q4 		$183 Hold
2
– – ﹤0.01% 368
2022
Q3 		$131 Hold
2
– – ﹤0.01% 357
2022
Q2 		$130 Hold
2
– – ﹤0.01% 350
2022
Q1 		$123 Hold
2
– – ﹤0.01% 345
2021
Q4 		$149 Buy
+2
New +$138 ﹤0.01% 344

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PFS Partners's GILD Position: Q2 2026 in Review

PFS Partners held its Gilead Sciences (GILD) position steady in Q2 2026 at 95 shares worth $12.1K. The position accounts for ﹤0.01% of the portfolio, ranked #363.

PFS Partners first reported a position in GILD in Q4 2021 and has held it in 19 quarters since. The position peaked at $13.2K in Q1 2026. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • PFS Partners held 95 shares of Gilead Sciences worth $12.1K as of Q2 2026.
  • PFS Partners left its Gilead Sciences share count unchanged in Q2 2026.
  • Gilead Sciences made up ﹤0.01% of PFS Partners's portfolio in Q2 2026, its #363 holding.
  • PFS Partners first reported a position in Gilead Sciences in Q4 2021 and has held it in 19 quarters since.
  • PFS Partners's Gilead Sciences position peaked at $13.2K in Q1 2026.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on PFS Partners's 13F filing for Q2 2026, filed 20 Jul 2026.